Phase 2
N=28
RAD001 in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Bottom Line
View on ClinicalTrials.gov: NCT00516165 ↗Enrolled (actual)
28
Serious AEs
25.0%
Results posted
Feb 2017
Primary outcome: Primary: Maximum Tolerated Dose of RAD001 in Patients With Advanced Hepatocellular Carcinoma (HCC). — 10 mg — p=0.05
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- RAD001 (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Massachusetts General Hospital
- Primary completion
- Jan 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximum Tolerated Dose of RAD001 in Patients With Advanced Hepatocellular Carcinoma (HCC). |
10 | 0.05 |
| PRIMARY Progression-free Survival Rate at 24 Weeks |
3.8 | <0.05 sig |
| SECONDARY Number of Patients With Adverse Events Who Were Treated With RAD001 for Advanced HCC |
28 | <0.05 sig |
| SECONDARY Overall Response Rate |
4 | 0.05 |
| SECONDARY Time to Progression |
3.9 | 0.05 |
| SECONDARY Overall Survival |
8.4 | 0.05 |
Summary
Laboratory studies have shown that RAD001 can prevent cells from multiplying. Consequently, the study drug is being tested in medical conditions in which excessive cell multiplication (as in cancer) needs to be stopped. The main purpose of this research study is to find the highest dose of RAD001 that can be given safely (without causing severe side effects) and to learn the effects (good or bad) RAD001 has on participants with liver cancer.
Eligibility Criteria
Inclusion Criteria
- Unresectable of metastatic HCC. Patients must have prior core biopsy to confirm the diagnosis of HCC and have archived tissues available for correlative studies
- At least one measurable site of disease according to RECIST criteria that has not been previously irradiated. If it has had previous radiation to teh marker lesion(s), there must be evidence of progression since the radiation
- 0-2 prior systemic chemotherapy and biologic regimens for hepatocellular carcinoma
- Patients with prior chemoembolization history can participate in the study if the chemoembolization was performed more than 4 weeks ago and patients must have measurable disease outside of prior chemoembolization field
- 18 years of age or older
- Minimum of 4 weeks since any major surgery or completion of radiation
- Minimum of 4 weeks since completion of all prior systemic anticancer therapy
- ECOG performance status of 0-2
- CLIP score of equal to or less then 3
- Adequate bone marrow, liver and renal function as outlined in the protocol
Exclusion Criteria
- Prior treatment with any investigational drug within the preceding 4 weeks
- Chronic treatment with systemic steroids or another immunosuppressive agent
- Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
- Patients with any severe and/or uncontrolled medical conditions or other condition that could affect participation in the study
- Known history of HIV seropositivity
- Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001
- Active, bleeding diathesis
- Women who are pregnant or breast feeding
- Patients who have received prior treatment with an mTor inhibitor
- Patients with known hypersensitivity to RAD001 or other rapamycins or its excipients
- History of non-compliance to medical regimens
- Patients with a positive dipstick for urine protein (reading of 2+ or greater) will then undergo a 24-hour urine collection for protein. If patients have a 2g or greater of protein/24hr, they will be excluded from the study.
Data sourced from ClinicalTrials.gov (NCT00516165). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.